To detennine if ciprofloxacin therapy alters the response to warfarin treatment, 36 adult patients attending three university-affiliated outpatient anticoagulation clinics randomly received a 12-day course of ciprofloxacin (750 mg twice daily) and a 12-day course of placebo; each course was separated by a 2-week washout period. Prothrombin times (Pfs), concentrations of S-warfarin and R-warfarin (the isomers of warfarin), and concentrations of clotting factors IT and VII were determined three times weekly for 9 weeks. By day 12 of ciprofloxacin therapy, concentrations of S-warfarin remained unchanged compared with those after placebo therapy, but R-warfarin concentrations increased significantly (1.15 times those after placebo therapy; P = .Oot); concentrations of clotting factors IT and VII decreased (0.903 and 0.872 times those after placebo therapy, respectively, P~.020). The mean Pf ratio after 12 days ofciprofloxacin therapy increased slightly (1.032 times that after placebo therapy; P = .057), but no patient had bleeding or a change in Pf that required alteration in warfarin or ciprofloxacin therapy. We conclude that warfarin therapy is not a contraindication to the use of ciprofloxacin.
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Certain quinolone antibacterial agents inhibit the hepatic metabolism of drugs, such as theophylline, thus resulting in toxicity [1] . Case reports have also suggested that quinolones can increase the response to warfarin, and bleeding has been described in patients treated with anticoagulants who received therapy with ciprofloxacin [2] [3] [4] [5] [6] [7] , nalidixic acid [8, 9] , norfloxacin [10] , and ofloxacin [11, 12] . One death purported to result from this interaction has been reported [10] . A review of case reports submitted to the Food and Drug Administration concluded that the quinolone-warfarin interaction is clinically important and that patients receiving therapy with the two drugs concomitantly should be monitored closely [13] . A recent review of drugs that interact with warfarin concluded that an interaction with ciprofloxacin was "probable" [14] .
In contrast, prospective, single-dose trials ofnorfloxacin [15 ] and enoxacin [16] found no significant effect on prothrombin time (PT). Healthy volunteers receiving low doses of warfarin therapy had no changes in PTs after temafloxacin was administered for 4 days [17] . Furthennore, two uncontrolled, multipledose trials of ciprofloxacin (500 mg twice a day) found no effect on PT in patients receiving chronic therapy with warfarin [18, 19] .
This study was undertaken to clarify the effects of concurrent ciprofloxacin administration on the pharmacokinetics and pharmacodynamics of warfarin. In this double-blind, placebo-controlled, randomized, crossover, multicenter trial, the largest recommended dose of ciprofloxacin was given for 12 days to patients receiving chronic anticoagulant therapy. Endpoints included clinical evidence of bleeding, serum concentrations of R-warfarin and S-warfarin (the isomers of warfarin), serum concentrations of clotting factors II and VII, and PTs. (International nonnalized ratio [INR] is currently recommended for monitoring the response to warfarin. However, this investigation was conducted when PT was in widespread use, and the anticoagulant response will be presented as PT or the PT ratio [patient PT / control PT].)
Methodology

Subjects
Adult patients attending the anticoagulation clinics at the three study sites in Richmond (Virginia), Minneapolis, and em 1996; 22 (February) Denver were recruited for the study from September 1990 through October 1991. A common protocol was approved by each site's institutional review board. Patients gave written informed consent before participation in the study and were eligible for enrollment if they had been receiving therapy with a constant dose of warfarin for at least 3 months and had stable PTs (defined as at least three determinations within 3 months that varied <2.5 seconds).
Patients were excluded from the study for the following reasons: severe cardiovascular disease, impaired hepatic or renal function, active peptic ulcer disease, gastrointestinal bleeding within the previous 12 months, epilepsy, cerebral arteriosclerosis, history of a serious psychiatric disorder, alcohol abuse within the previous 12 months or unwillingness to limit alcohol consumption to no more than two drinks per day, unwillingness to avoid all over-the-counter drugs, receiving medications known to interact with ciprofloxacin, and treatment with ciprofloxacin within the preceding 10 weeks. In the week before the study began, eligible patients underwent physical examination, hepatitis screening, and drug screening (of urine), and a complete medical history was obtained. Routine hematologic, blood chemistry, and urine tests were also performed; these tests were done again at the completion of the study.
Study Design
The trial lasted 9 weeks for each patient. The first week was an observational period for determining the patient's compliance with warfarin therapy and the patient's ability to maintain a daily food and medication diary. During week 1, patients remained eligible for the study if all three PTs did not deviate > 2.5 seconds from the mean prestudy value. During weeks 2 and 3, patients received a l2-day course of either ciprofloxacin (750 mg; batch no. KQ-10-87) or an identically appearing placebo twice a day. Weeks 4 and 5 served as a treatment washout period. During weeks 6 and 7, patients received the alternate regimen. Weeks 8 and 9 constituted a final washout period.
Patients were interviewed three times a week to determine compliance, side effects, and dietary changes. Compliance was assessed by inspection of food and medication diaries, weekly tablet counts, and blood concentrations of ciprofloxacin and warfarin. Safety was evaluated by monitoring adverse events, particularly thrombosis or bleeding episodes, and by measuring PTs. An increase or decrease of 40% from the mean pretreatment PT resulted in additional determinations and evaluation of PT.
Sampling Schedule
Patients were instructed to take their usual dose of warfarin at 9:00 A.M. for the duration of the study. Ciprofloxacin or placebo was taken at 7:00 A.M. and 7:00 P.M. During each of the 9 weeks, blood for determination of PTs, serum concentrations of clotting factors II and VII, and serum concentrations of R-warfarin and S-warfarin was obtained before the warfarin dose was given every Monday, Wednesday, and Friday. Beginning in week 2, blood for determination of ciprofloxacin concentrations was obtained each Friday morning before the warfarin dose was administered. PTs were determined on the day that the specimens were obtained as described below.
Blood for determination of ciprofloxacin and warfarin concentrations was collected in nonheparinized tubes and was kept frozen at -70°C. Blood samples for determination of clotting factor concentrations were collected in tubes containing citrate; the plasma was separated and frozen at -70°C until analysis.
Analytical Methods
Ciprofloxacin concentrations were determined by high-performance liquid chromatography (HPLC) according to a previously validated method [20] at Bayer Pharmaceutical Division (West Haven, CT). Plasma concentrations of R-warfarin and S-warfarin were determined by HPLC with use of a modification of a previously described method [21] at Oneida Research Services (Whitesboro, NY). Concentrations of factor II and factor VII were determined at the Special Coagulation Laboratory at the Veterans Affairs Medical Center in Denver. Activities of factors II and VII were quantified by one-stage clotting-time bioassays with factor II-or factor VII-deficient plasma, thromboplastin, and normal pooled plasma or subject plasma as substrates. Clotting times (average of duplicate sampies) were determined for normal pooled plasma at five dilutions by means of an automated coagulation instrument, and a standard curve was prepared by plotting the average clotting time vs. the plasma concentration. Factor II and factor VII activities were calculated by interpolation. The within-day coefficient of variations for factor II and factor VII were~7% and~5%, respectively. PTs were determined at each site by the Coag-a-mate X 2 photooptical technique [22] .
Statistical Analysis
Logarithmically transformed PTs, clotting factor concentrations, and warfarin concentrations were subjected to a mixedeffects analysis of variance, including terms for site, treatment sequence, patient within site and treatment sequence, treatment period, and treatment. The longest PT and day 12 PTs were the primary outcome variables. Concentrations of R-warfarin and S-warfarin and concentrations of factors II and VII were the secondary outcome variables. The ratios of these variables (ciprofloxacin to placebo) were estimated, and a two-sided 90% confidence interval for each ratio is presented, as are the results of a two-tailed test of equality of the treatments. A 
Results
Thirty-six patients were enrolled in the study, and 32 completed the full 9-week treatment course. Four subjects withdrew from 70 the study prematurely for reasons unrelated to the study. Two of these patients dropped out early (~2 weeks) and are not described; the other two dropped out during the final 2-week washout period and are included in the study as they had already completed both the placebo and ciprofloxacin treatment arms.
Of the 34 patients in the final analysis, 33 were men and one was a woman. The patients' ages ranged from 42 to 80 
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Days of therapy years (mean ± SD, 64.5 ± 8.1 years), and the patients' weights ranged from 62 to 143 kg (mean ± SD, 86.9 ± 18.6 kg).
Weekly warfarin doses ranged from 20 to 70 mg (mean ± SD, 42 ± 13 mg). Sixteen adverse events were recorded during ciprofloxacin treatment, and 18 were recorded during placebo treatment. Most of these events were mild and resolved promptly. Adverse events considered by investigators to be possibly related to ciprofloxacin therapy included decrease in blood glucose level, nausea, and tremulousness. Adverse events thought to be related to placebo therapy included difficulty in swallowing liquids, slight increase in alanine aminotransferase level, diarrhea (two patients), and decrease in hemoglobin level and hematocrit. There were no significant site or treatment sequence effects.
The rate of compliance estimated from pill counts was 99%. All patients receiving ciprofloxacin therapy had measurable ciprofloxacin concentrations that ranged from 0.55 to 5.39 p,g/ mL (mean ± SD: week I, 2.6 ± 1.4 p,g/mL; week 2, 2.4 ± 1.1 p,g/mL).
The influence ofciprofloxacin on outcome variables is shown in figures 1-3. The results of statistical analysis are shown in table 1. At day 12, ciprofloxacin therapy caused statistically Table 1 . Significance of differences of ciprofloxacin and placebo treatments for primary and secondary endpoints. .015
.229
significant reductions in concentrations of clotting factor II (ciprofloxacin/placebo ratio = 0.903; P = .012) and concentrations of clotting factor VII (ciprofloxacinl placebo ratio = 0.872; P = .020) and a significant increase in R-warfarin concentrations (ciprofloxacin/placebo ratio = 1.147; P = .001).
There was an increase in the day 12 mean PT of 3% (ciprofloxacin/placebo ratio = 1.032; P = .057). The upper end of the 90% confidence interval for the PT ratio was 1.06 (a 6% increase in the mean PT ratio), which corresponds to a 1-second increase in PT. In other words, the true maximum effect (with 90% certainty) would correspond to an increase in mean PT from 18 seconds (1.5 times a control of 12 seconds) to 19 seconds. In contrast to the preceding results, there was no significant change in concentrations of S-warfarin either at the maximum effect or by day 12 (ciprofloxacin/placebo ratio = 0.940).
Discussion
Results from this trial are similar to those from previous uncontrolled trials [18, 19] : ciprofloxacin therapy has little effect on PT. The mean concentration of R-warfarin increased by 15% compared with the control, while concentrations of clotting factors II and VII decreased by 10% and 13%, respectively. However, the subsequent effects on PT were of no clinical significance. No patient receiving placebo or ciprofloxacin therapy had isolated elevations in PT that required withdrawal from the study.
These findings are most consistent with the following interpretation. Although ciprofloxacin can inhibit the metabolism of certain drugs, such as theophylline, it appears to be a specific inhibitor of CYP1A2 [23] . In contrast, the rate-limiting step for metabolism of S-warfarin is CYP2C9 [24] . Concentrations of S-warfarin, which is approximately five to eight times more potent than R-warfarin, did not change [25] . While the metabolic fate of R-warfarin is not well characterized, the increase in R-warfarin concentrations found in this study and those found by Toon et al. [16] suggest that CYP1A2 is important. The slight increase in R-warfarin concentrations found in this study is sufficient to cause a modest decline in clotting factor concentrations. The increase in PT seen in this study, while not reaching the conventional level of significance, is probably real but of little clinical importance.
The different reports of substantial increases in PTs during concomitant therapy with ciprofloxacin and warfarin are at variance with results of prospective trials. It seems reasonable to conclude that one of two possibilities is likely true: either ciprofloxacin therapy does result in clinically important increases in anticoagulant effects (but this is a rare and idiosyncratic event) or case reports of such an interaction are confounded. It is possible that there are suppressive effects of "infection" on the activity of hepatic microsomal enzymes [26] . Infection is known to decrease the metabolism of a number of drugs, and it is possible that increased PTs and bleeding in patients receiving therapy with warfarin and quinolones actually are caused by reduced warfarin clearance during infection. We conclude that therapy with ciprofloxacin, and probably other quinolones, is not contraindicated for patients who are receiving warfarin treatment. However, as with any new drug that is added to therapy for a patient receiving warfarin treatment, it is still prudent to monitor the anticoagulation response.
